Pharma & Biotech Daily: “Revolutionizing Therapies: Autoimmune Advances and Oncological Expansions”

Date: February 18, 2026
Host: Pharma and BioTech News

Episode Overview

This episode offers a rapid, insightful roundup of the latest breakthroughs, deals, regulatory changes, and funding trends impacting pharma and biotech. The host explores new therapeutic expansions (notably in autoimmune and cancer indications), major company moves, regulatory shifts, and the evolving investment landscape. Timely innovations in ophthalmology, rare disease, cell and gene therapy, and mental health are featured, highlighting how the industry is pivoting to address unmet needs with cutting-edge science and strategic adaptability.

Key Discussion Points & Insights

1. Autoimmune Therapy Expansion: Roche’s Goxiva

• [00:20–00:55]
  • Roche’s Goxiva, originally an oncology antibody, is making waves with strong Phase 3 results in immune-mediated kidney diseases.
  • Previously approved for lupus nephritis, Goxiva’s success in kidney autoimmune indications could “mark a potential paradigm shift from oncology to autoimmune therapy applications.”
  • Insight: Highlights the emerging power of immune modulation for severe non-oncology conditions.

2. Oncology Developments: Eli Lilly & Synthetic Lethality

• [00:56–01:43]
  • Eli Lilly is broadening Retevmo’s use, now exploring it as adjuvant therapy for non-small cell lung cancer beyond its initial rare biomarker approvals.
    • Quote: “This effort reflects a broader trend...companies are increasingly looking to extend the application of targeted therapies beyond their initial indications.” (00:56)
  • Gilead’s $1.5 billion acquisition of a synthetic lethal therapy from Genhouse Bio underscores “growing interest in synthetic lethality as a novel cancer treatment approach—targeting tumors while sparing normal cells.”

3. Ophthalmology Innovation: Ocular Therapeutix’s Axpaxli

• [01:44–02:06]
  • Ocular prepares for FDA filing after Axpaxli outperformed Regeneron’s Eylea in Phase 3 wet AMD trials.
  • Despite “investor skepticism, Ocular remains confident” in Axpaxli’s transformative clinical benefit.
  • Insight: The host notes fierce competition in retinal disease, with innovative therapies poised to redefine standards of care.

4. GLP-1 and Obesity: Lilly’s Orforglipron Launch Prep

• [02:07–02:25]
  • Lilly is strategically stockpiling orforglipron, its oral GLP-1, ahead of anticipated FDA approval for obesity.
  • This aims to “prevent supply chain issues seen during previous GLP1 launches” and reflects a broad industry focus on product launch readiness.

5. Regulatory and Market Shifts

• [02:26–03:20]
  • Policy: Trump-era 340B rebates are being piloted again to tackle drug pricing.
  • Supply Chain: Novartis’ long-term deal with Niowave secures Actinium-225 supply for future radiopharmaceuticals, vital for precision oncology.
  • Financing: Biopharma funding expected to “recover steadily by 2026—but with a cautious approach favoring de-risked assets.”
    • Quote: “Venture capitalists prefer predictable returns amidst an evolving market landscape.” (03:13)

6. Global & Strategic Updates

• [03:21–03:48]
  • Japan: Innovacel, with $92 million planned IPO, signals renewed biotech investor interest in the region.
    • Quote: “Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.” (03:42)

7. Mental Health & Psychedelics: Compass Pathways

• [03:49–04:22]
  • Compass Pathways reports positive pivotal Phase 3 results for psilocybin (Comp360) in treatment-resistant depression.
    • Quote: “The success of this Phase three trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options for patients who have exhausted traditional therapies.” (04:14)
  • Data shows notable durability of benefit, exceeding FDA requirements.

8. Rare Disease & Regulatory Hurdles

• [04:23–05:06]
  • Biohaven’s CEO laments FDA delays affecting rare disease treatment access, citing broader “regulatory processes that can impede innovation and delay life saving treatments.”
  • Moderna’s mRNA flu vaccine faces rejection from FDA, while other countries ease approval for innovative therapies.
  • DISC Medicine’s FDA path for bitobridin (rare disease) is questioned due to reliance on outdated trial protocols.

9. Innovative R&D: AI and Organoids

• [05:07–05:23]
  • Integration of AI and organoid technology in R&D “promises expedited drug discovery timelines while reducing costs.”

10. Gene Therapy & CRISPR: Vertex and Crispr Therapeutics

• [05:24–05:39]
  • Vertex and Crispr Therapeutics aim for $500 million in revenue via Cascavy, a gene therapy for rare diseases—signaling commercial viability and transformative patient impact from CRISPR technology.

Notable Quotes & Memorable Moments

• Roche’s shift from oncology to autoimmunity:
  “This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders.” (00:34)

• On trend in oncology drug extensions:
  “Companies are increasingly looking to extend the application of targeted therapies beyond their initial indications.” (00:59)

• On investor risk appetite:
  “Venture capitalists prefer predictable returns amidst an evolving market landscape.” (03:13)

• On mental health and psychedelics:
  "The success of this Phase three trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments..." (04:14)

• On systemic regulatory headwinds:
  “These frustrations reflect broader industry challenges with regulatory processes that can impede innovation and delay life saving treatments.” (04:33)

Timestamps for Key Segments

• Autoimmune Expansion: 00:20–00:55
• Oncology Drug Indication Expansion & Gilead Acquisition: 00:56–01:43
• Ophthalmology / Ocular Therapeutix Update: 01:44–02:06
• GLP-1 Supply Strategy: 02:07–02:25
• Pricing/Rebates, Radiopharma Supply, Funding Trends: 02:26–03:20
• Global/Japan IPO Movement: 03:21–03:48
• Mental Health/Psychedelics: 03:49–04:22
• Rare Disease & Regulatory Issues: 04:23–05:06
• AI & Organoids in R&D: 05:07–05:23
• CRISPR Gene Therapy Prospects: 05:24–05:39

This episode succinctly highlights biotech’s momentum in diversifying drug indications, deploying next-gen technology, navigating regulatory complexities, and strategically financing innovation to meet future healthcare challenges.